The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Anders Fink-Jensen, Professor of Psychiatry at the University of Copenhagen and a consultant psychiatrist, about the emerging role of GLP-1 receptor agonists in addiction treatment. We examine the clinical observations that initiated this research, findings from a randomized trial of semaglutide for alcohol use disorder, possible effects on craving, dosing considerations, and the evidence still needed before broader clinical use. Listen now on all major platforms."Semaglutide reduced both total alcohol consumption and the number of heavy drinking days."Meet the guest: Dr. Anders Fink-Jensen is a professor at the University of Copenhagen and a consultant psychiatrist. His research focuses on psychopharmacology, addiction, severe mental illness, and the clinical evaluation of GLP-1 receptor agonists in people with alcohol use disorder. Listen to Dr. Anders Fink-Jensen on The GLP-1 Podcast Show, available on all major platforms.Want to stay up to date on the latest GLP-1 research and updates? Subscribe and never miss an episode.Liked this one? Don’t stop now. Here’s what we think you’ll love!What you will learn:(00:00) Highlight(02:06) Introduction(03:03) Origins of addiction research(07:24) Semaglutide trial design(12:06) Alcohol use outcomes(18:10) Patient selection(23:33) Future clinical research(27:06) Closing thoughtsThe GLP-1 Podcast Show is trusted and supported by innovative companies like:- ZentrixOS- Zentrix Insights- Elevate- WiseVAs𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.Website: The GLP-1 Podcast ShowInstagram: The GLP-1 Podcast ShowLinkedIn: The GLP-1 Podcast ShowYouTube: The GLP-1 Podcast ShowFacebook: The GLP-1 Podcast ShowTikTok: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Jon Campbell, Associate Professor of Medicine at Duke University, about the changing science of GIP and glucagon. We examine GIP physiology, glucagon signaling, weight-independent metabolic effects, multi-receptor agonism, and variability in treatment response. Discover how emerging pharmacology could shape more precise obesity treatment. Listen now on all major platforms. "GI think it’s going to take a little while, but people are going to come around to this idea that glucagon, particularly when combined with an incretin like GIP or GLP-1, is a really powerful way to improve metabolic disease." Meet the guest: Dr. Jon Campbell is an Associate Professor of Medicine at Duke University. His research examines incretin hormones, pancreatic islet biology, and the cellular mechanisms that regulate glucose metabolism. His work has helped advance understanding of GIP, GLP-1, glucagon, and the signaling pathways that may shape future metabolic therapies. Listen to Dr. Jon Campbell on The GLP-1 Podcast Show, available on all major platforms. What you will learn: (00:00) Highlight (01:02) Introduction (02:09) GIP biology (06:04) Hormone contributions (11:45) Optimized agonists (15:33) Glucagon actions (19:21) Multi-hormone therapies (25:46) Closing thoughts The GLP-1 Podcast Show is trusted and supported by innovative companies like: - Zentrix Insights (https://zentrixinsights.com/) - ZentrixOS (https://zentrixos.com/) - WiseVAs (https://www.wisevas.io/) - Elevate (https://elevateagents.ai/) 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://theglp1podcast.com/ LinkedIn: https://www.linkedin.com/showcase/the-glp-1-podcast-show/ Instagram: https://www.instagram.com/theglp1podcast/ Facebook: https://www.facebook.com/profile.php?id=61577863745840 TikTok: https://www.tiktok.com/@theglp1podcast

In this episode of The GLP-1 Podcast Show, I speak with Dr. Michael Nauck, Head of Clinical Research at the Diabetes Division of St. Josef-Hospital, Ruhr-University Bochum, Germany. We explore the early discoveries behind incretin hormones, the development of GLP-1–based therapies, and their expanding role in diabetes, obesity, and cardiovascular care. Dr. Nauck also discusses the next generation of dual and triple agonists shaping obesity medicine. Listen now on all major platforms. “For the first time, weight loss medications, like GLP-1, achieved meaningful reductions without serious safety concerns.” Meet the guest: Dr. Michael Nauck is Head of Clinical Research at the Diabetes Division, St. Josef-Hospital, Ruhr-University Bochum, Germany. His pioneering work on incretin hormones established the scientific foundation for GLP-1–based therapies in type 2 diabetes. With a research focus on metabolic regulation and cardiovascular outcomes, Dr. Nauck continues to advance innovation in endocrinology and obesity care. What you will learn: (00:00) Highlight (00:46) Introduction (01:55) Incretin effect explained (06:15) Early GLP-1 discoveries (08:16) DPP-4 inhibitors’ role (11:49) Beyond glucose control (16:21) Mechanisms of GLP-1 (22:28) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://www.wisenetix.com/glp1 Instagram: https://www.instagram.com/theglp1podcast/ LinkedIn: https://www.linkedin.com/showcase/the-glp-1-podcast-show/

A whole new era of communication in GLP-1 is here!Now you’ve got the sharpest minds in GLP-1 research right in your pocket. What’s best?You can listen to them while driving to the hospital, walking between labs, traveling, or just running errands. Now it’s never been this good or this simple.Welcome to The GLP-1 Podcast Show, a monthly podcast where you’ll hear cutting-edge perspectives and what’s working in the world of GLP-1.Our aspiration is to be the first place you are going to go to find out what's happening, the latest breakthroughs, clinical updates, and innovations in GLP-1 care and research.